5.330USD-2.47%Mkt Cap: —P/E: 16.501d ago
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value175.07M $
Revenue (TTM)215.72M $
Gross Profit202.22M $
Net Income (TTM)-274.85M $
Revenue/Share3.627 USD
Last Price5.330 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees533
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)16.50
P/E (Forward)—
PEG—
EV/EBITDA-0.99
EV/Revenue0.81
P/S—
P/B1.47
EPS (TTM)0.32
EPS (Forward)—
52W Range
5.12037% of range5.690
52W High5.690 USD
52W Low5.120 USD
Profitability
Gross Margin93.74%
Oper. Margin-126.28%
EBITDA Margin-82.07%
Profit Margin-127.41%
ROE-77.81%
ROA-22.38%
Growth
Revenue Growth-3.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-142.33M $
CapEx (TTM)—
FCF Margin-40.20%
FCF Yield—
Net Debt-147.20M $
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity10.37
Current Ratio1.61
Quick Ratio1.40
Book Value/Sh3.642 USD
Cash/Share2.812 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.52.45M
Float51.04M
Insiders6.61%
Institutions83.47%
Technical
SMA 504.086 (+30.4%)
SMA 2004.824 (+10.5%)
Beta0.64
S&P 52W Chg18.16%
Avg Vol (30d)11.79K
Avg Vol (10d)952
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—